PT - JOURNAL ARTICLE AU - Perkins, Griffith B. AU - Tunbridge, Matthew J. AU - Chai, Cheng Sheng AU - Hope, Christopher M. AU - Yeow, Arthur Eng Lip AU - Salehi, Tania AU - Singer, Julian AU - Shi, Bree AU - Masavuli, Makutiro G. AU - Mekonnen, Zelalem Addis AU - Garcia-Valtanen, Pablo AU - Kireta, Svjetlana AU - Johnston, Julie K. AU - Drogemuller, Christopher J. AU - Sim, Beatrice Z. AU - Spencer, Shane M. AU - Sallustio, Benedetta C. AU - Comerford, Iain AU - Bouras, George AU - Weiskopf, Daniela AU - Sette, Alessandro AU - Aggarwal, Anupriya AU - Milogiannakis, Vanessa AU - Akerman, Anouschka AU - Turville, Stuart AU - Hurtado, Plinio R. AU - Ying, Tracey AU - Hissaria, Pravin AU - Barry, Simon C. AU - Chadban, Steven J. AU - Grubor-Bauk, Branka AU - Coates, P. Toby TI - mTOR inhibition improves the formation of functional T cell memory following COVID-19 vaccination of kidney transplant recipients AID - 10.1101/2023.03.27.23287773 DP - 2023 Jan 01 TA - medRxiv PG - 2023.03.27.23287773 4099 - http://medrxiv.org/content/early/2023/03/29/2023.03.27.23287773.short 4100 - http://medrxiv.org/content/early/2023/03/29/2023.03.27.23287773.full AB - Inadequate immune response to vaccination is a long-standing problem faced by immunosuppressed kidney transplant recipients (KTRs), requiring novel strategies to improve vaccine efficacy. In this study, the potential of mechanistic target of rapamycin inhibitors (mTORi) to improve T cell responses to COVID-19 vaccination was investigated. Following primary vaccination with adenoviral (ChAdOx1) or mRNA (BNT162b2) COVID-19 vaccines, KTRs receiving rapamycin demonstrated T cell responses greater than those of healthy individuals, characterized by increased frequencies of vaccine-specific central memory, effector memory and TEMRA T cells, in both the CD4+ and CD8+ compartments. Relative to standard-of-care triple therapy, mTORi-based therapy was associated with a 12-fold greater functional T cell response to primary vaccination of KTRs. The use of rapamycin to augment T cell responses to COVID-19 booster (third dose) vaccination was next investigated in a randomized, controlled trial. Immunosuppression modification with rapamycin was feasible and well-tolerated, but did not improve vaccine-specific T cell responses in this cohort. To understand the parameters for effective use of rapamycin as a vaccine adjuvant, mice were treated with rapamycin before primary or booster vaccination with ancestral and/or Omicron COVID-19 vaccines. Supporting the findings from KTRs, significant enhancement of functional and stem-like memory T cell responses was observed when rapamycin was administered from the time of primary, rather than booster, vaccination. Collectively, a positive effect of mTOR inhibitors on vaccine-induced T cell immunity against COVID-19 in humans was demonstrated.One Sentence Summary Rapamycin use at the time of primary COVID-19 vaccination augments the formation of functional, vaccine-specific T cell memory in immunosuppressed kidney transplant recipients.Competing Interest StatementAlessandro Sette is a consultant for Gritstone Bio, Flow Pharma, Moderna, AstraZeneca, Qiagen, Fortress, Gilead, Sanofi, Merck, RiverVest, MedaCorp, Turnstone, NA Vaccine Institute, Emervax, Gerson Lehrman Group and Guggenheim. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. All other authors declare no competing interests.Clinical TrialACTRN12621000532808; ACTRN12621001412820Clinical Protocols https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06634-w Funding StatementThis work has received funding from The Hospital Research Foundation Group (outside of structured grant round) and the Health Services Charitable Gifts Board (HSCGB; project grant, 70-05-52-05-20), and was supported by NIH contract 75N93019C00065 (A.S, D.W). GBP and MJT received support from the Mary Overton Research Fellowship (HSCGB) and Jacquot Research Scholarship (Royal Australasian College of Physicians), respectively.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Human Research Ethics Committee of the Central Adelaide Local Health Network gave ethical approval for human studies. The Animal Ethics Committee of the University of Adelaide gave ethical approval for animal studies.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript or available upon reasonable request to the authors.